Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …

The complicated interplay between cancer and the host immune system has been studied
for decades. New insights into the human immune system as well as the mechanisms by …

Immune-based therapies for cancer are generating substantial interest because of the
success of immune checkpoint inhibitors. This study aimed to enhance anticancer immunity …

Generating responses to tumor antigens poses a challenge for immunotherapy. This phase
II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment …

Abstract Purpose: PD-1/L1 axis–directed therapies produce clinical responses in a subset of
patients; therefore, biomarkers of response are needed. We hypothesized that quantifying …

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA)
family, and has been identified as one of the most immunogenic tumor-associated antigens …

Therapeutic cancer vaccines aim to induce durable antitumor immunity that is capable of
systemic protection against tumor recurrence or metastatic disease. Many approaches to …

Dendritic cells (DC) are key regulators of both innate and adaptive immunity, and the array
of immunoregulatory functions exhibited by these cells is dictated by their differentiation …

The Toll-like receptor (TLR) 7/8 agonist resiquimod has been used as an immune adjuvant
in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen …